Lv54
1430 积分 2024-04-17 加入
Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti‐epidermal Growth Factor Receptor Antibody
16天前
已完结
Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model‐Informed Dose Selection in Oncology First‐in‐Human Study: A Case of Roblitinib (FGF401)
19天前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
19天前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
19天前
已完结
Application of Pharmacometrics in Advancing the Clinical Research of Antibody-Drug Conjugates: Principles and Modeling Strategies
20天前
已完结
Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology
20天前
已完结
FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
27天前
已完结
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
29天前
已完结
A Guide to Rational Dosing of Monoclonal Antibodies
1个月前
已完结
Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies
1个月前
已完结
皖公网安备34019202002308
